Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BIIB122 (DNL151) in Parkinson's disease with pathogenic LRRK2 variants
2022-000747-77Phase 3Completed
- Sponsor
- Biogen
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB122 225 mg with Placebo (2 arms). Primary endpoint: Time to confirmed worsening in MDS-UPDRS Parts II and III combined score. Started Jul 2022; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2022-000747-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000747-77.